PanGenomic Health, Inc. Class A (TSE:NARA)
:NARA
Want to see TSE:NARA full AI Analyst Report?
NARA Stock Chart & Stats
C$0.51
C$0.04(33.33%)
At close: 4:00 PM EST
C$0.51
C$0.04(33.33%)
Day’s Range― - ―
52-Week RangeC$0.19 - C$2.57
Previous CloseN/A
Volume0.00
Average Volume (3M)110.39K
Market Cap
C$5.48M
Enterprise ValueC$5.65M
Total Cash (Recent Filing)C$38.77K
Total Debt (Recent Filing)C$212.87K
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Aug 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding14,046,870
10 Day Avg. Volume77,322
30 Day Avg. Volume110,395
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-3.87
Price to Sales (P/S)0.00
P/FCF Ratio-4.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Industry ExposurePanGenomic sits in Medical - Healthcare Information Services, a sector suited to recurring data and analytics revenue. Structural demand for healthcare information services can underpin durable customer adoption and long-term contract opportunities if the company reaches product-market fit.
Lean Operating FootprintA headcount of five implies an extremely lean cost base and low fixed payroll. This reduces near-term cash burn per employee, can extend runway from existing financing, and allows management to iterate products or pivot with lower structural overhead than larger competitors.
Evidence Of Cost ControlThe income statement notes losses narrowed sharply in 2024 vs 2023, indicating management can enact meaningful expense reductions or efficiency gains. Sustained cost discipline is a durable advantage that improves odds of reaching breakeven as revenue ramps.
Bears Say
No Meaningful RevenueThe company reports essentially no revenue from 2020–2025, showing it is not operating at commercial scale. Without material sales, margins and operating leverage remain unproven, forcing continued dependence on external financing and increasing long-term execution risk.
Negative Equity & Rising DebtNegative shareholders' equity across 2022–2025 and higher debt in 2025 reflect accumulated deficits and tighter balance sheet flexibility. This structural weakness constrains access to capital, raises insolvency and covenant risks, and increases likelihood of dilutive financing.
Persistent Cash BurnOperating and free cash flows are negative each year, with a sizable outflow in 2025, demonstrating persistent cash burn. Ongoing negative cash generation necessitates repeated financing, limits investment capacity, and creates structural runway and funding risks if markets tighten.
PanGenomic Health, Inc. Class A News
NARA FAQ
What was PanGenomic Health, Inc. Class A’s price range in the past 12 months?
PanGenomic Health, Inc. Class A lowest stock price was C$0.18 and its highest was C$2.57 in the past 12 months.
What is PanGenomic Health, Inc. Class A’s market cap?
PanGenomic Health, Inc. Class A’s market cap is C$5.48M.
When is PanGenomic Health, Inc. Class A’s upcoming earnings report date?
PanGenomic Health, Inc. Class A’s upcoming earnings report date is Aug 04, 2026 which is in 75 days.
How were PanGenomic Health, Inc. Class A’s earnings last quarter?
Currently, no data Available
Is PanGenomic Health, Inc. Class A overvalued?
According to Wall Street analysts PanGenomic Health, Inc. Class A’s price is currently Overvalued.
Does PanGenomic Health, Inc. Class A pay dividends?
PanGenomic Health, Inc. Class A does not currently pay dividends.
What is PanGenomic Health, Inc. Class A’s EPS estimate?
PanGenomic Health, Inc. Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PanGenomic Health, Inc. Class A have?
PanGenomic Health, Inc. Class A has 14,046,870 shares outstanding.
What happened to PanGenomic Health, Inc. Class A’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PanGenomic Health, Inc. Class A?
Currently, no hedge funds are holding shares in TSE:NARA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PanGenomic Health, Inc. Class A
Pangenomic Health Inc., a precision health company, develops a self-care digital platform to deliver personalized and evidence-based information about natural treatments to support mental health. It develops the Nara App, a mobile app that provides consumers with a knowledge base tailored to an individual's unique user profile; and the PlantGx Platform, a digital therapeutics clinic platform that provides health practitioners with access to user health data enabled from the Nara App by the patient and to receive patient referrals. The company was formerly known as Zetta Capital Corp. and changed its name to PanGenomic Health Inc. in December 2021. Pangenomic Health Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Technical Analysis
Diagnos
―
nDatalyze Corp
―
Rocket Doctor AI
―
UniDoc Health Corp
―
DiagnaMed Holdings Corp.
―
Options Prices
Currently, No data available
---